Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2006-06-13
2006-06-13
Navarro, Mark (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S185100, C424S193100, C424S234100, C424S235100, C424S236100, C424S237100, C424S244100, C530S300000, C530S350000
Reexamination Certificate
active
07060277
ABSTRACT:
The invention relates to peptides comprising an amino acid sequence homologous to the amino sequence of a fragment of a pyrogenic exotoxin, and functional derivatives of said peptides, capable of eliciting protective immunity against toxic shock induced by a pyrogenic exotoxin or by a mixture of pyrogenic exotoxins. Preferred peptides comprise an amino acid sequence homologous to the amino sequence of a fragment ofStaphylococcal aureusenterotoxin B (SEB). The invention also relates to broad spectrum pharmaceutical compositions for the treatment, protection against or short term prophylaxis of toxin-mediated activation of T cells, comprising as active ingredient at least one peptide according to the invention or derivative thereof, and to broad spectrum vaccines for conferring long term immunity against toxic shock induced by at least one pyrogenic exotoxin are provided. The vaccines comprising as active ingredient at least one peptide according to the invention, or derivative thereof.
REFERENCES:
patent: 5310874 (1994-05-01), Tamura et al.
patent: 5407609 (1995-04-01), Tice et al.
patent: 5705151 (1998-01-01), Dow et al.
patent: 5716637 (1998-02-01), Anselem et al.
patent: WO 98/29444 (1998-07-01), None
Abrahmsén, et al., “Characterization of two distinct MHC class II binding sites in the superantigen staphylococcal enterotoxin A”, The EMBO Journal, vol. 14, No. 13, pp. 2978-2986, (1995).
Andersen, et al., “The structure of cyclin H: common mode of kinase activation and specific features”, The EMBO Journal, vol. 16, No. 5, pp. 958-967, (1997).
Arad, et al., “Transient Expression of Human Interleukin-2 and Interferon-□ Genes Is Regulated by Interaction between Distinct Cell Subsets”, Cellular Immunology, vol. 160, 240-247 (1995).
Betley, et al., “Nucleotide Sequence of the Type A Staphylococcal Enterotoxin Gene”, Journal of Bacteriology, Jan. vol. 170, No. 1. p. 34-41, (1988).
Bohach, et al., “Staphylococcal and Streptococcal Pyrogenic Toxins Involved in Toxic Shock Syndrome and Related Illnesses”, Crit. Rev. Microbiol. vol. 17, p. 251 (1990).
Bohach, et al., “Nucleotide sequence of the staphylococcal enterotoxin C1 gene and relatedness to other pyrogenic toxins”, Mol Gen Genet vol. 209:15-20, (1987).
Bohach, et al., “Conservation of the Biologically Active Portions of Staphylococcal Enterotoxins C1 and C2”, Infection and Immunity, vol. 57, No. 7, p. 2249-2252, (1989).
Brander, et al., “Peptide immunization in humans: a combined CD8+/CD4+T cell-targeted vaccine restimulates the memory C4 T cell response but fails to induce cytotoxic T lymphocytes (CTL)”, Clin Exp Immunol, vol. 105:18-25 (1996).
Buelow, et al., “Localization of the Immunologic Activity in the Superantigen Staphylococcal Enterotoxin B Using Truncated Recombinant Fusion Proteins”, The Journal of Immunology, vol. 148, 1-6, No. 1, pp. 1-6, (1992).
Cardarelli, et al., “The Collagen Receptor α2β1, from MG-63 and HT1080 Cells, Interacts with a Cyclic RGD Peptide”, The Journal of Biological Chemistry, vol. 267, No. 32, pp. 23159-23164, (1992).
Choi, et al., “Interaction of Staphylococcus aureus toxin “superantigens” with human T cells”, Proc. Natl. Acad. Sci, USA, vol. 86, pp. 8941-8945, (1989).
Choi, et al., “Residues of the variable region of the T-cell-receptor β-chain that interact withS.aureustoxin superantigens”, Nature, vol. 346, (1990).
Chomczynski, et al., “Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-Chloroform Extraction”, Analytical Biochemistry, vol. 162, pp. 156-159 (1987).
Cho, et al., “Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations”, Science, vol. 265, pp. 346-355 (1994).
Couch, et al., “Cloning and Nucleotide Sequence of the Type E Staphylococcal Enterotoxin Gene”, Journal of Bacteriology, vol. 170, No. 7, p. 2954-2960, (1988).
Dyer, et al., “A Synthetic Peptide Mimic of Plasma Apolipoprotein E That Binds the LDL Receptor”, The Journal of Biological Chemistry, vol. 266, No. 34, pp. 22803-22806, (1991).
Fleischer, et al., “T Cell Stimulation By Staphylococcal Enterotoxins”, J. Exp. Med., vol. 167, 1697-1707, (1988).
Fraser, John D., “High-affinity binding of staphylococcal enterotoxins A and B to HLA-DR”, Nature, vol. 338, pp. 221-223, (1989).
Gerez, et al., “Aberrant Regulation of Interleukin-2 but Not of Interferon-( Gene Expression in Down Syndrome (Trisomy 21)”, Clinical Immunology and Immunopathology, vol. 58, 251-266 (1991).
Gilon, et al., “Backbone Cyclization: A New Method for Conferring Conformational Constraint on Peptides”, Biopolymers, vol. 31, 745-750 (1991).
Herman, et al., “SUPERANTIGENS: Mechanism of T-Cell Stimulation and Role in Immune Responses”, Annu. Rev Immunol. vol. 9, pp. 745-72, (1991).
Hoffman, et al., “Predictions of T-Cell Receptor- and Major Histocompatibility Complex-Binding Sites on Staphylococcal Enterotoxin C1”, Infection and Immunity, vol. 62, No. 8, p. 3396-3407, (1994).
Hughes, et al., “Ability of Synthetic peptides representing epitopes of outer membrane protein F ofPseudomonas aeruginosato afford protection againstP. aeruginosainfection in a murine acute pneumonia model”, Vaccine, vol. 13, No. 18, pp. 1750-1753, (1995).
Hudson, et al., “Staphylococcal Enterotoxin A has Two Cooperative Binding Sites on Major Histocompatibility Complex Class II”, J. Exp. Med., vol. 182, pp. 711-720 (1995).
Ikejima, et al., “Induction of Human Interleukin-1 by a Product ofStaphylococcus aureusAssociated with Toxic Shock Syndrome”, J. Clin. Invest., vol. 73, pp. 1312-1320. (1984).
Janeway, Charles A. Jr., “Self Superantigens?”, Cell, vol. 63, pp. 659-661, (1990).
Janeway, Jr., et al., “T-Cell Responses to M1s and to Bacterial Proteins that Mimic its Behavior”, Immunological Reviews, No. 107,.pp. 61-88, (1989).
Jardetzky, et al., Superantigen SEB, Protein Data Bank, PDB code 1SEB, Deposited Nov. 26, 1995, Released Jun. 20, 1996.
Jardetzky, et al., “Three-Dimensional structure of a human class II histocompatibility molecule complexed with superantigen,” Nature, vol. 268, pp. 711-718, (1994).
Jeffrey, et al., “Crystal Structure of the Tetramerization Domain of the p53 Tumor Suppressor at 1.7 Angstroms”, Science, vol. 267, pp. 1498-1502,(1995).
Jett, et al., “Identification of Staphylococcal Enterotoxin B Sequences Important for Induction of Lymphocyte Proliferation by Using Synthetic Peptide Fragments of the Toxin”, Infection and Immunity, vol. 62, No. 8., p. 3408-3415, (1994).
Kaempfer, et al., “Prediction of Response to Treatment in Superficial Bladder Carcinoma Through Pattern of Interleukin-2 Gene Expression”, Journal of Clinical Oncology, vol. 14, No. 6, pp. 1778-1786, (1996).
Kappler, et al., “Mutations Defining Functional Regions of the Superantigen Staphylococcal Enterotoxin B”, J. Exp. Med. vol. 175, pp. 387-396 (1992).
Hoffmann, Michelle, “Superantigens“ May Shed Light on Immune Puzzle””, Science, vol. 248, pp. 637-784 (1990).
Ketzinel, et al., “Regulation of Human Interleukin-2 and Interferon-Gamma Gene Expression by Suppressor T Lymphocytes”, Scand. J. Immunol. vol. 33, 593-605, (1991).
Komisar, et al., “Localization of Binding Sites of Staphylococcal Enterotoxin B (SEB), a Superantigen, for HLA-DR by Inhibition with Synthetic Peptides of SEB”, Infection and Immunityp. vol. 62, No. 11, pp. 4775-4780 (1994).
Kuchroo, et al., “A Single TCR Antagonist Peptide Inhibits Experimental Allergic Encephalomyelitis Mediated by a Diverse T Cell Reppertoire”, The Journal of Immunology, vol. 153, p. 3326. (1994).
Kussie, et al., “Structure of the MDM2 Oncopro
Arad Gila
Kaempfer Raymond
Browdy and Neimark, PLC
Navarro Mark
Yissum Research Development Company of the Hebrew University of
LandOfFree
Broad spectrum antagonists and vaccines directed against... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Broad spectrum antagonists and vaccines directed against..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Broad spectrum antagonists and vaccines directed against... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3658344